Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Expands By 9.2%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 603,700 shares, a growth of 9.2% from the June 30th total of 552,600 shares. Currently, 10.7% of the shares of the company are sold short. Based on an average daily volume of 101,200 shares, the short-interest ratio is currently 6.0 days.

bioAffinity Technologies Price Performance

bioAffinity Technologies stock opened at $2.49 on Thursday. bioAffinity Technologies has a 12-month low of $0.95 and a 12-month high of $3.62. The company has a current ratio of 2.22, a quick ratio of 2.21 and a debt-to-equity ratio of 0.14. The firm has a 50 day simple moving average of $2.32 and a 200-day simple moving average of $2.13.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.21) earnings per share for the quarter. bioAffinity Technologies had a negative net margin of 171.43% and a negative return on equity of 134.34%. The firm had revenue of $2.41 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group began coverage on bioAffinity Technologies in a research report on Tuesday, July 23rd. They issued a “buy” rating and a $6.00 target price on the stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.